Report of Foreign Issuer (6-k)
January 13 2020 - 6:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of January, 2020
Commission File Number: 001-37353
BIONDVAX PHARMACEUTICALS LTD.
(Translation of registrant’s name
into English)
Jerusalem BioPark, 2nd Floor
Hadassah Ein Kerem Campus
Jeusalem, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BiondVax Pharmaceuticals
Ltd. (hereinafter, the “Registrant”, the “Company”, or “BiondVax”) announces that it will hold
an Annual General Meeting of Shareholders on February 11, 2020, at 4:00 p.m. Israel time, at the offices of Gross, Kleinhendler,
Hodak, Halevy, Greenberg, Shenhav & Co., One Azrieli Center, Tel Aviv 6701101, Israel.
The
Company hereby furnishes the following documents:
|
i.
|
Notice and Proxy Statement with respect to the Company’s Annual
General Meeting of Shareholders to be held on February 11, 2020, describing the proposals
to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related
to the meeting; and
|
|
ii.
|
Proxy Card whereby holders of Company’s shares may
vote at the meeting without attending in person.
|
The Notice and Proxy Statement is furnished
with this Form 6-K as Exhibit 99.1 and the Proxy Card is furnished with this Form 6-K as Exhibit 99.2.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
BiondVax Pharmaceuticals Ltd.
|
|
|
|
Date: January 13, 2020
|
By:
|
/s/ Ron Babecoff
|
|
|
Ron Babecoff
|
|
|
Chief Executive Officer
|
2
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
From Apr 2023 to Apr 2024